Health
Malaria Vaccine Roll-Out Looks To I Save Thousands Of Lives
In a groundbreaking development, a new malaria vaccine has the potential to save hundreds of thousands of lives over the coming decade. This remarkable advancement, spearheaded by Sir Adrian Hill, professor of vaccinology at the University of Oxford, represents a significant leap forward in the fight against one of the world’s deadliest diseases.
The R21/Matrix-M vaccine, developed at the university’s Jenner Institute under Sir Adrian’s leadership, is the first to achieve the World Health Organization’s (WHO) target of 75% efficacy in preventing malaria. The initial doses of this life-saving vaccine were administered in the Ivory Coast on Monday, marking the beginning of a new era
in malaria prevention.
Speaking on BBC Radio 4’s Today programme, Sir Adrian expressed his optimism about the vaccine’s impact. “I think during this decade, we can reduce malaria deaths from half a million a year to maybe 200,000 if things go well,” he stated. “Then, ultimately, probably next decade will see a really serious attempt at eliminating and eradicating malaria.”
The journey of R21/ Matrix-M began in 2012, and its development has been steadily progressing since then. One of the key advantages of this vaccine is its affordability. Priced at just under four dollars per dose, it is significantly cheaper than the original malaria vaccine, which costs between nine and ten dollars per dose. This cost-effectiveness is crucial for low-income countries, where malaria is most prevalent and financial resources are limited.
“This is why the development of R21/Matrix-M is so important,” Sir Adrian explained. “Everyone sees this as an affordable vaccine, making it realistic to roll out tens of millions of doses from now on.”
The vaccine is administered to children at five, six, and seven months of age, with doses given four weeks apart, followed by a booster a year later. It works by priming the blood with antibodies that target the malaria protein known as circumsporozoite protein (CSP).
This development has been met with widespread acclaim, as it brings hope to millions of people living in malaria-endemic regions. The prospect of significantly reducing malaria-related deaths and ultimately eradicating the disease is now within reach, thanks to the tireless efforts of Sir Adrian Hill and his team at the University of Oxford.
As the world watches the rollout of R21/Matrix-M in the Ivory Coast, there is renewed optimism that this vaccine will transform the fight against malaria and save countless lives in the years to come.
Health
Trump Proposes Five-Way Split of Childhood Vaccines
Trump Proposes Five-Way Split of Childhood Vaccines
President Donald Trump has proposed splitting some childhood vaccines into five separate doses administered six months apart, a plan that vaccine experts say could leave children inadequately protected if the individual doses contain too little vaccine.
Trump made the proposal on Friday while speaking about his administration’s plans to alter the United States childhood immunisation schedule.
He said children could receive doses labelled one through five, with each containing what he described as about 20 per cent of the usual amount.
“Instead of a child going in and having a tremendous amount of different vaccines pumped into a big proportion of the body … we’re going to recommend that they do five doses marked one, two, three, four, five and that they be given in six-month intervals,” Trump said.
Trump did not identify all the vaccines that would be affected. He specifically referred to the polio vaccine, which he described as having been “amazing”.
However, vaccine specialist Dr Paul Offit, director of the Vaccine Education Centre at the Children’s Hospital of Philadelphia, said the proposed approach would not provide the intended protection.
Offit explained that vaccines are developed through dose-response studies to determine the smallest quantity capable of producing a protective immune response.
“You don’t want to give too much, where you know you don’t need all that, and you don’t want to give too little,” he said.
He told CNN that administering vaccines at doses below the level required to generate an immune response could make them ineffective rather than safer.
Trump also linked the proposed changes to autism, saying he expected them to lead to a “massive reduction” in autism.
However, decades of scientific research have found no causal link between childhood vaccines and autism.
The President’s comments came amid broader efforts by his administration to alter federal childhood vaccination policy.
In August, Trump signed an executive order seeking changes to the childhood immunisation schedule, including separating the measles, mumps and rubella vaccine into individual shots.
The administration has argued that the changes would reduce the number of vaccines given to children and address concerns about the existing schedule.
Health and Human Services Secretary Robert F. Kennedy Jr., who was with Trump as he outlined the proposal, has also backed changes to federal vaccine policy.
Kennedy spoke on Thursday at a conference organised by Children’s Health Defense, an organisation associated with vaccine scepticism.
Health
DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus
DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus
The Democratic Republic of Congo has received 70,000 doses of the Ervebo Ebola vaccine from the global vaccine stockpile as health authorities intensify efforts to contain an outbreak of Bundibugyo virus disease.
The doses were released by the International Coordinating Group on Vaccine Provision following a request from the DRC government last week.
The development comes amid uncertainty over the effectiveness of Ervebo against the Bundibugyo strain, which is different from the Zaire ebolavirus for which the vaccine was originally developed and licensed.
Of the 70,000 doses, 20,000 have been allocated for a Phase 3 clinical trial designed to assess the vaccine’s potential impact against the Bundibugyo virus, while 50,000 doses will be administered to frontline and health workers in line with recommendations from the World Health Organisation’s Strategic Advisory Group of Experts on Immunization.
The effectiveness of Ervebo against Bundibugyo virus in humans is currently unknown.
However, preliminary laboratory and animal studies have suggested that the vaccine could offer some protection, prompting researchers to investigate its potential through the clinical trial.
The trial is expected to generate evidence that could guide future decisions on the use of Ervebo in outbreaks involving the Bundibugyo strain.
Health authorities have also stressed the importance of informed consent, saying people offered the vaccine must be adequately informed about its potential risks, benefits and limitations in relation to the current outbreak.
The ICG is made up of the WHO, International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières and UNICEF, while Gavi, the Vaccine Alliance, funds the global vaccine stockpile.
The WHO and Africa Centres for Disease Control and Prevention welcomed the allocation, supporting the DRC’s efforts to protect affected communities and contain the outbreak through a community-led response.
Both organisations said they would continue to support the DRC government in protecting communities, saving lives and generating scientific evidence that could strengthen Africa’s preparedness for future viral outbreaks.
The Bundibugyo outbreak has renewed attention on the need for effective vaccines and rapid scientific responses to emerging infectious diseases, with the outcome of the DRC trial expected to provide important information for future outbreak control.
Health
Africa CDC, WHO demand urgent scale-up of DRC Ebola response
Africa CDC, WHO demand urgent scale-up of DRC Ebola response
The Africa Centres for Disease Control and Prevention and the World Health Organisation have called for an urgent scale-up of the community-led response to the Ebola outbreak in the Democratic Republic of the Congo.
The organisations said the response must focus on early detection, contact tracing, access to treatment, protection of frontline health workers and faster deployment of resources to affected communities.
The call followed a joint high-level mission to Uganda and the DRC on August 4 and 5, led by the WHO Director-General, Dr Tedros Adhanom Ghebreyesus; Director-General of Africa CDC, Dr Jean Kaseya; and WHO Regional Director for Africa, Dr Mohamed Janabi.
The delegation visited Kampala, Bunia and Kinshasa, where it held discussions with government officials, response coordinators, health workers, community representatives and development partners.
In Uganda, the delegation commended the country for successfully containing local transmission after it declared the end of its outbreak on July 28.
Uganda recorded 20 confirmed cases and two deaths, while all identified contacts completed their follow-up.
The organisations said Uganda’s experience demonstrated the importance of early detection, rapid contact tracing, coordinated government action, community engagement and effective cross-border surveillance.
However, they warned that continued transmission in the DRC meant neighbouring countries remained at risk and should maintain surveillance, laboratory readiness and cross-border coordination.
The delegation subsequently travelled to Bunia, the epicentre of the outbreak in Ituri Province, where it met provincial authorities, health workers, community leaders and response partners.
It also visited the Rwangole Ebola Treatment Centre to assess its readiness to expand access to timely and quality care.
The delegation stressed that communities would play a central role in containing the outbreak, urging authorities to ensure that residents receive accurate information from trusted sources and can report suspected cases and seek treatment without fear.
It also identified community, religious, women and youth leaders as critical partners in building confidence and ensuring that response measures reflect local realities.
-
News1 week agoTrump’s Bomber Pullout: Iran Threat Tests US-UK Security Alliance
-
News1 week agoFormer German spy chief arrested over alleged espionage
-
News1 week agoCaribbean states seek stronger regional aviation safety oversight
-
Analysis1 week agoWill Africa Follow Niger Republic? By Alabidun Shuaib AbdulRahman
-
News1 week agoTinubu declares three days’ mourning over NAF crash
-
News1 week ago10-Year-Old Rainikemba Igbokwe Publishes First Book, Small Boy, Big God
